Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 14/20 | 0.58 |
| ▸ | RAB9A | P51151 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078959 | 0.84 | PTGER1 (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2558910 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2080164 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL13162807 | 0.80 | HRH3 (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3435648 | 0.80 | PTGER1 (0.56) | SMN1; SMN2RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL2079022 | 0.79 | MAPT (0.51) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3435877 | 0.79 | HRH3 (0.52) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12291571 | 0.79 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3435678 | 0.79 | PTGER1 (0.59) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3550523 | 0.78 | PTGER1 (0.46) | SMN1; SMN2RAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101426774-B | Azolecarboxamide derivative | ASTELLAS PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101426774-A | Azolecarboxamide derivative | ASTELLAS PHARMA INC (JP) | 2009-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SMN1; SMN2 3601/4885RAB9A 4401/4885NPC1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.